Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
Want to see ORIC full AI Analyst Report?
ORIC Stock Chart & Stats
$10.75
-$0.67(-7.21%)
At close: 4:00 PM EST
$10.75
-$0.67(-7.21%)
Day’s Range― - ―
52-Week Range$4.52 - $14.93
Previous CloseN/A
Volume181.02K
Average Volume (3M)2.30M
Market Cap
$980.50M
Enterprise Value$913.26M
Total Cash (Recent Filing)$281.49M
Total Debt (Recent Filing)$11.55M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
May 11, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding100,358,240
10 Day Avg. Volume1,749,899
30 Day Avg. Volume2,304,275
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.30
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.85K
Enterprise Value/Ebitda-6.83
Forecast
1Y Price Target
$21.33Price Target Upside98.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Dose Optimization And Regulatory PathDose optimization results for rinzimetostat combinations could define a registrational dose and enable initiation of a pivotal Phase 3 prostate cancer trial, creating a clear development path for approval.
Pipeline Clinical ReadoutsMultiple planned clinical readouts across the pipeline, including dose optimization and updated lung cancer data, represent discrete catalysts that could materially revalue the stock if they confirm tolerability and activity.
Safety DifferentiationSafety profile of rinzimetostat combined with androgen receptor inhibitors appears more favorable than competing regimens, which could prompt clinician preference and quicker adoption given similar efficacy.
Bears Say
Class Safety ConcernsVoluntary withdrawal of a peer drug due to secondary blood cancer reports has heightened safety concerns across the drug class, increasing regulatory scrutiny and pressuring investor sentiment.
Competitive Dynamics And Market TimingA crowded competitive field and any delay to market entry relative to larger competitors could materially erode market penetration even if efficacy and safety are comparable.
Data Robustness And Tolerability UncertaintySmall patient samples, early discontinuations, and frequent dose reductions in some programs limit confidence in efficacy durability and complicate tolerability assessment, raising the risk of disappointing outcomes.
Oric Pharmaceuticals News
ORIC FAQ
What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was $4.52 and its highest was $14.93 in the past 12 months.
What is Oric Pharmaceuticals’s market cap?
Oric Pharmaceuticals’s market cap is $980.50M.
When is Oric Pharmaceuticals’s upcoming earnings report date?
Oric Pharmaceuticals’s upcoming earnings report date is May 11, 2026 which is in 8 days.
How were Oric Pharmaceuticals’s earnings last quarter?
Oric Pharmaceuticals released its earnings results on Feb 23, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.04.
Is Oric Pharmaceuticals overvalued?
According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued.
Does Oric Pharmaceuticals pay dividends?
Oric Pharmaceuticals does not currently pay dividends.
What is Oric Pharmaceuticals’s EPS estimate?
Oric Pharmaceuticals’s EPS estimate is -0.32.
How many shares outstanding does Oric Pharmaceuticals have?
Oric Pharmaceuticals has 100,358,240 shares outstanding.
What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
Oric Pharmaceuticals reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went up 14.603%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals?
Currently, no hedge funds are holding shares in ORIC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oric Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.33 (98.45% Upside)
$21.33 (98.45% Upside)
Blogger Sentiment
Neutral
ORIC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 18.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
125.36%
12-Months-Change
Fundamentals
Return on Equity
-38.79%
Trailing 12-Months
Asset Growth
48.52%
Trailing 12-Months
Company Description
Oric Pharmaceuticals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Stock 12 Month Forecast
Average Price Target
$21.33
▲(98.45% Upside)
Technical Analysis
Spyre Therapeutics
―
Trevi Therapeutics
―
Praxis Precision Medicines
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
1.08% Insiders
14.17% Mutual Funds
0.86% Other Institutional Investors
72.36% Public Companies and
Individual Investors